Rainer Henning
Directeur Général chez Biomay AG
Profil
Rainer Henning is currently the Chief Executive Officer at Biomay AG.
Prior to this, he was the President & Chief Executive Officer at FIBREX Medical, Inc. from 2010 to 2013.
He also worked as the Managing Director-Research & Development at Sanofi-Aventis U.S.
LLC.
Postes actifs de Rainer Henning
| Sociétés | Poste | Début |
|---|---|---|
Biomay AG
 Biomay AG BiotechnologyHealth Technology Biomay AG researches and develops disease modifying allergy therapeutics. The firm discover and develop recombinant allergy vaccines with a superior efficacy and safety profile and these innovative vaccines are based on cutting edge science for immunotherapy and prophylaxis. It offers cGMP contract manufacturing services for the production of recombinant biologicals as active pharmaceutical ingredients. The company was founded in 1984 and is headquartered in Vienna, Austria. | Directeur Général | - |
Anciens postes connus de Rainer Henning
| Sociétés | Poste | Fin |
|---|---|---|
FIBREX Medical, Inc.
 FIBREX Medical, Inc. Miscellaneous Commercial ServicesCommercial Services FIBREX Medical Inc. is a development stage bio-pharmaceutical company. Its operational affiliate FIBREX Medical Research & Development GmbH was established in Vienna in February 2001. The company was founded to convert high impact scientific discovery into pharmaceutical products for important diseases. The company aims to become a leader in the development and commercialization of pharmaceuticals targeting fundamental mechanisms of inflammation and tissue injury. While inflammation is highly desirable to defend the organism against foreign particles and infections, it can become harmful and destructive if it runs unchecked. Inflammation-based tissue injury is well known as a major component in the pathogenesis and progression of important diseases such as myocardial infarction, septic and hemorrhagic shock, graft rejection, or rheumatoid arthritis. In addition, endothelial dysfunction in inflamed tissues leads to capillary leak and deleterious edema formation, aggravating organ dysfunction. | President | 05/02/2013 |
Sanofi-Aventis U.S. LLC
 Sanofi-Aventis U.S. LLC Pharmaceuticals: MajorHealth Technology Sanofi-Aventis U.S. LLC engages in the provision of pharmaceutical products. It discovers, develops, produces and markets innovative therapies. The firm extensive research and development efforts are focused on health care challenges in cardiology, oncology and internal medicine, as well as metabolic diseases, central nervous system disorders, ophthalmology and vaccines. The company is headquartered in Bridgewater, NJ. | Directeur Technique/Scientifique/R&D | - |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 3 |
|---|---|
FIBREX Medical, Inc.
FIBREX Medical, Inc. Miscellaneous Commercial ServicesCommercial Services FIBREX Medical Inc. is a development stage bio-pharmaceutical company. Its operational affiliate FIBREX Medical Research & Development GmbH was established in Vienna in February 2001. The company was founded to convert high impact scientific discovery into pharmaceutical products for important diseases. The company aims to become a leader in the development and commercialization of pharmaceuticals targeting fundamental mechanisms of inflammation and tissue injury. While inflammation is highly desirable to defend the organism against foreign particles and infections, it can become harmful and destructive if it runs unchecked. Inflammation-based tissue injury is well known as a major component in the pathogenesis and progression of important diseases such as myocardial infarction, septic and hemorrhagic shock, graft rejection, or rheumatoid arthritis. In addition, endothelial dysfunction in inflamed tissues leads to capillary leak and deleterious edema formation, aggravating organ dysfunction. | Commercial Services |
Sanofi-Aventis U.S. LLC
Sanofi-Aventis U.S. LLC Pharmaceuticals: MajorHealth Technology Sanofi-Aventis U.S. LLC engages in the provision of pharmaceutical products. It discovers, develops, produces and markets innovative therapies. The firm extensive research and development efforts are focused on health care challenges in cardiology, oncology and internal medicine, as well as metabolic diseases, central nervous system disorders, ophthalmology and vaccines. The company is headquartered in Bridgewater, NJ. | Health Technology |
Biomay AG
Biomay AG BiotechnologyHealth Technology Biomay AG researches and develops disease modifying allergy therapeutics. The firm discover and develop recombinant allergy vaccines with a superior efficacy and safety profile and these innovative vaccines are based on cutting edge science for immunotherapy and prophylaxis. It offers cGMP contract manufacturing services for the production of recombinant biologicals as active pharmaceutical ingredients. The company was founded in 1984 and is headquartered in Vienna, Austria. | Health Technology |
